Cellebrite Appoints Shiven Ramji as CEO and Lowers FY26 ARR and Revenue Outlook
CLBT is trading near its 52-week low of $11.02 (6.9% above the low).
Summary
Cellebrite named Shiven Ramji as CEO and reduced FY26 ARR and revenue guidance, citing longer sales cycles, while increasing adjusted EBITDA targets.
Key Events · Earnings and Guidance · CLBT
-
CEO Transition
Effective immediately, Shiven Ramji, who has served as President of Products and Technology since May 2026, succeeds Thomas E. Hogan as CEO. Ramji will also join the board.
-
FY26 Guidance Cut
Full-year ARR outlook is lowered to $550M-$560M (14-16% growth) and revenue to $555M-$561M (17-18% growth), down from prior expectations due to longer sales cycles and slower Inseyets conversions.
-
Adjusted EBITDA Raised
The full-year adjusted EBITDA target is raised to $153M-$159M (~28% margin), up from the original target, reflecting operating discipline.
-
Q3 2026 Guidance
For Q3, ARR is expected at $524M-$528M, revenue at $145M-$148M, and adjusted EBITDA at $42M-$45M.
Analysis · CLBT · Technology
A CEO transition and a cut to full-year ARR and revenue guidance, offset by a higher adjusted EBITDA target, mark a meaningful reset for a premium-priced company. The lowered outlook reflects longer sales cycles and slower Inseyets conversions, while the CEO change introduces execution uncertainty. However, the raised EBITDA target signals cost discipline.
At the time of this filing, CLBT was trading at $11.78 on NASDAQ in the Technology sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $11.02 to $19.98. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.